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Unraveling the racial disparities associated with kidney disease.
In the United States, chronic kidney disease (CKD), and in
particular end-stage renal disease (ESRD), represent a growing
problem. Many other countries also have an increasing num-
ber of ESRD cases. Racial/ethnic disparities have been doc-
umented globally in the prevalence, incidence, and treatment
of CKD, most extensively in the United States, but also in the
United Kingdom, Australia, and New Zealand, among others.
In many circumstances, these disparities are of a negative na-
ture, that is, certain racial/ethnic groups fare worse than their
white counterparts with respect to the treatment or outcome
of CKD. However, in a few circumstances, they are of a pos-
itive nature, such as the survival advantage seen in minorities
with ESRD compared with whites. The reasons for racial dis-
parities in the prevalence, incidence, and treatment of CKD are
not fully understood, although they are explained partly by co-
existing medical conditions and modifiable risk factors, such as
socioeconomic, lifestyle, and cultural. It is likely, however, that
the complete picture incorporates a complex interaction be-
tween these sociocultural, genetic, and environmental factors.
In a global society that prides itself on a high level of sensitivity
and equality, there is an ethical and moral imperative to address
the continuing racial/ethnic disparities in CKD and many of the
factors underlying this epidemic. We review data highlighting
the racial/ethnic disparities that exist in the incidence and treat-
ment of CKD, with particular emphasis on ESRD. A better
understanding of both the negative and positive racial/ethnic
disparities may yield important insights, which can inform fu-
ture research strategies and improve health outcomes for all
patients afflicted with CKD.
Chronic kidney disease (CKD), and the subsequent
progression to end-stage renal disease (ESRD), impose
a relentless socioeconomic burden on patients, society,
and the health care system. Over the last decade, the
number of ESRD patients in the United States grew at
an exponential rate, doubling from 201,454 in 1991 to
1See Editorial by Pugsley, p. 1364.
Key words: chronic kidney disease, culture, dialysis, end-stage renal dis-
ease, ethnic groups, racial disparities, socioeconomic, transplantation.
Received for publication September 28, 2003
and in revised form May 26, 2004, and October 13, 2004
Accepted for publication May 6, 2005
C© 2005 by the International Society of Nephrology
406,081 in 2001. Although this growth rate has begun
to slow, projections to the end of this decade are sober-
ing, with over 700,000 patients estimated to be receiving
ESRD treatment by 2010: 404,406 white, 241,591 African
Americans, and 78,570 other [1]. The continued growth
of the ESRD population has substantial public policy
implications. Moreover, it is estimated that one in nine
Americans, more than 20 million individuals, has CKD,
but most are unaware of their condition [2]. Another
20 million Americans are at increased risk of develop-
ing kidney disease. The costs associated with ESRD are
substantial, with an estimated global cost of $76,515 per
patient-year [3], with a total cost of treating ESRD in the
United States of $22.8 billion in 2001 [4], and Medicare
costs expected to increase to almost $40 billion by 2010
[5].
It has long been recognized that ESRD is more com-
mon in certain racial/ethnic groups [6–8]. These dispari-
ties have been extensively reported in the United States,
with African Americans having the highest reported inci-
dence and prevalence of treated ESRD [Third National
Health and Nutrition Examination Survey (NHANES
III, 1988-1994)] [9]. The African American population
is not an exception; American Indians, Alaskan Natives,
Asians, Native Hawaiians and other Pacific Islanders, and
Hispanics all have higher incidence and prevalence rates
of treated ESRD than whites. Similar racial/ethnic dispar-
ities have been reported in other countries, including the
United Kingdom, Australia, and New Zealand [10–12].
A persistently elevated serum creatinine level is an in-
dicator of CKD and an independent predictor of CKD
progression [abstract; Norris K, et al, J Am Soc Nephrol
14:190A, 2003]. The highest levels of serum creatinine
are seen in men, African Americans, and the elderly.
African Americans, Native Americans, Asian Americans,
and Hispanics are respectively 3.9, 2.7, 1.6, and 1.5 times
more likely than white Americans to develop ESRD
(Fig. 1) [4, 13, 14]. An increase in both the prevalence
and recognition of CKD coupled with a growing and
aging population contribute significantly to the relent-
less rise in the occurrence of ESRD. The burden that
this places on certain racial/ethnic groups, in particular,
and society as a whole, is of great concern. Indeed, the
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Fig. 1. The incidence of reported end-stage
renal disease (ESRD) in the United States in
2001, by race and ethnicity adjusted for age
and gender [4]. Data from the United States
Renal Data System 2003.
Healthy People 2010 Initiative has made the reduction
of racial/ethnic disparities associated with CKD a cen-
tral United States national health priority [15]. As noted
above, the potential reasons for racial/ethnic inequalities
in CKD are multifactorial [16, 17]. A concerted effort will
therefore be required to unravel the factors underlying
these disparities.
RACIAL DISPARITIES IN THE RISK FACTORS
FOR CKD
Excess prevalence of key risk factors for CKD in
racial/ethnic minorities plays an important role in the
excess rate of ESRD in these groups. Higher rates of
diabetes mellitus, hypertension, and glomerulonephritis,
and other factors such as dietary and lifestyle, influence
the progression of CKD, and the response to treatment.
Recognition of these risk factors can lead to more proac-
tive preventive and early treatment strategies.
Diabetes mellitus
It is estimated (NHANES III, 1988-1994) that 8% of
adults in the United States have type 2 diabetes mellitus
[18], and the incidence of this disease is increasing [4]. The
number of cases of diabetes mellitus, and consequently di-
abetic nephropathy, is also rising progressively worldwide
[19]. Diabetic nephropathy occurs in about one third of
patients with diabetes mellitus, and is the most common
cause of ESRD in most industrialized nations accounting
for nearly half of new ESRD cases [4, 20].
Relative to the non-Hispanic white population, the in-
cidence of diabetes mellitus is, respectively, 1.6, 1.5, and
2.3 times higher in African American, Hispanic, and Na-
tive American populations. Not surprisingly, substantial
racial disparities exist in the incidence of diabetes-related
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Fig. 2. The incidence of reported type 2 diabetes–related end-stage
renal disease (ESRD) in the United States by race; combined data for
1998−2001 [4]. Rates adjusted for gender. Data from the United States
Renal Data System 2003.
ESRD, with Native Americans suffering from the high-
est rates (Fig. 2) [4, 18]. In addition to having a greater
incidence of diabetes mellitus, the onset of albuminuria
appears to present much earlier in the course of dia-
betes mellitus in African Americans compared with white
Americans. Thaler et al [21] and Goldschmid et al [22]
reported that as many as 25% of African Americans
916 Norris and Agodoa: Racial disparities associated with kidney disease
may show albuminuria less than a year after diabetes
mellitus has been diagnosed, suggesting delayed diagno-
sis or more aggressive disease progression.
Data from the TransPacific Renal Network, reported
in 2000, indicated that diabetes mellitus may account for
over 55% of incident ESRD in Asian Americans and
other Pacific Islanders [23], a figure that exceeds the
United States national average [24, 25]. Furthermore,
Grandinetti et al [26] reported the prevalence of diabetes
mellitus among Native Hawaiians may be as high as 22%
in some rural communities, a rate three times the preva-
lence seen in United States whites [26]. They hypothe-
sized that these communities have a genetic susceptibil-
ity to diabetes mellitus which is unmasked as the result
of obesity arising from a high-fat Western diet and phys-
ical inactivity [27]. Indeed, this “thrifty” genotype, which
allows the body to compensate for cycles of physical ac-
tivity/rest and feast/famine by storing fuel in periods of
starvation, could lead to obesity and type 2 diabetes mel-
litus given a Westernized, sedentary lifestyle. The thrifty
genotype is thought to occur at higher rates among those
racial/ethnic groups who previously thrived in environ-
ments with deficient or inconsistent food sources [28, 29].
Hypertension
Hypertension may be associated with arteriolar
nephrosclerosis and impaired kidney function. It is both a
risk factor for, and complication of, CKD [30, 31]. Indeed,
in 2000, 27% of all incident ESRD patients in the United
States had hypertension reported as their primary cause
of ESRD [32]. Recent data from the 1999-2000 NHANES
noted that while African Americans (34%) have higher
rates of hypertension than whites (29%) or Hispanics
(21%), the rate of blood pressure control is dramatically
lower (<140/90 mm Hg) in Hispanics at 18%, in compari-
son with 28% for African Americans and 33% for whites
[33]. In addition, the incidence of hypertension associ-
ated with CKD is substantially higher among African
Americans than whites [4, 34, 35]. In 1997, the 16-year
findings from the Multiple Risk Factor Intervention Trial
(MRFIT) showed that, among hypertensive patients, the
incidence of all-cause ESRD per 100,000 person-years of
hypertension was 16.38 for African Americans, but only
3.00 for white Americans [34]. Other factors such as the
higher rate of low birth weight among African Americans
compared with whites, and the associated low nephron
count, may predispose to hypertension and kidney dis-
ease [36]. As a significant relationship exists between
ESRD and low birth weight in African Americans, dif-
ferences in fetal development in African Americans may
contribute to the racial disparity in ESRD.
Dietary factors and lifestyle
A high caloric, high carbohydrate, and high salt diet
with low potassium, magnesium, and calcium intake are
risk factors for hypertension; in particular, a high salt diet
is a risk factor for the development of hypertension. An
increased sensitivity to high levels of dietary sodium could
also help explain the more rapid deterioration of kidney
function seen in hypertensive African Americans com-
pared with white Americans [37, 38].
Physical inactivity and obesity also contribute to ex-
cessive rates of diabetes mellitus, hypertension, and ul-
timately CKD [39], and are disproportionately high in
racial/ethnic minorities. The prevalence of physical inac-
tivity is particularly high in African American females
at 55% compared with 36% for white females, 44% for
African American males, and 33% for white males [40].
Obesity and overweight prevalence rates were also high-
est among African American females (77%, compared
with 57% for white females, 61% for African American
males, and 67% for white males) [40]. More than half of
African American females aged 40 years or older were
obese and more than 80% were overweight. Also signifi-
cant is the finding that 20% of African American children
aged 6 to 11 years and 24% of African American adoles-
cents aged 12 to 19 years were overweight [40]. The future
health consequences of these high levels of obesity and
overweight are likely to be staggering; therefore, health
programs should focus on reducing excessive caloric in-
take and increasing physical activity.
Glomerulonephritis and immunoglobulin
A nephropathy
Glomerulonephritis is a well-established risk factor
for CKD and immunoglobulin A (IgA) nephropathy is
the most common form of primary glomerulonephri-
tis. The prevalence of IgA nephropathy varies among
racial groups, being more common in Native Americans
from New Mexico [41] and the Chinese population
[42], and rare in African Americans. While the rate of
glomerulonephritis-related ESRD is second only to dia-
betes among indigenous Australians, there does not ap-
pear to be a specific increase in IgA nephropathy [43]. IgA
nephropathy is associated with immune complex depo-
sition, glomerulosclerosis, interstitial fibrosis, and tubu-
lar atrophy [44]. The exact causes of IgA nephropathy
and the pathogenesis of the disease are unknown, al-
though it may be associated with respiratory tract infec-
tions [45] and liver disease, including heavy alcohol intake
[46–48].
In 2000, glomerulonephritis was a major cause of
ESRD among Filipino patients in Hawaii undergoing
dialysis, accounting for 24% of cases [23]. This figure
was twofold higher than in the continental United States
ESRD population. This higher prevalence of glomeru-
lonephritis may be related to the higher rates of IgA
nephropathy among Asians worldwide.
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Fig. 3. Sociocultural influences on racial/ethnic minority health with implications for chronic kidney disease (CKD) [49]. Modified from Cunning-
ham (BMJ 2003).
RACIAL DISPARITIES IN THE TREATMENT
OF CKD
Socioeconomic factors
Socioeconomic status has been shown to have a sig-
nificant impact on the incidence and treatment of ESRD
[16, 17]. Socioeconomic factors, such as low income, poor
education, residence in a low-income areas, and conse-
quently poor access to health care, are strong predictors
for the development of ESRD (Fig. 3) [49–52].
In 1995, Hajnal [53] noted that, of people living in
areas of urban poverty in the United States, 67% were
African American, 20% were Hispanic, and 12% were
white. Furthermore, the proportion of nonelderly African
American and Hispanic populations considered to be be-
low the federal poverty level ($14,128 for a family of
three in 2001) was 31% and 29%, respectively, compared
with 11% of the white population [54]. Poverty is often
associated with suboptimal housing settings (redlining),
often leading to excess exposure to toxic dumps and en-
vironmental toxins such as lead. Studies have shown that
environmental exposure to lead is associated with an in-
creased risk of hypertension and impaired renal function
[55, 56]. The NHANES III study found that compared
with whites African Americans have higher blood lead
concentrations, which are associated with elevated blood
pressure and hypertension [57].
Reduced socioeconomic status negatively influences
access to health care, access to kidney transplants, and
mortality in patients with ESRD [58–63]. In 2001, 55%
of Hispanic and 45% of African American populations
were uninsured or received publicly funded health care,
compared with 22% of the white population [54]. Hence,
the poorest individuals, despite having the greatest need
for medical care, often receive the least. Delayed referral
of patients with CKD to specialist care limits the poten-
tial for timely intervention that could slow disease pro-
gression or prevent complications, and is associated with
prolonged hospital stays, increased expense, and higher
mortality rates [64, 65]. In the United States, racial/ethnic
minorities are much less likely than whites to be referred
to a nephrologist and undergo renal replacement ther-
apy in a timely manner [64, 66]. This is due, at least in
part, to socioeconomic factors, such as poverty and lack
of health insurance [67–69]. However, the findings of a re-
cent population-based study indicate that the situation is
likely to be more complex; Powe et al showed that socioe-
conomic status and race did not adversely affect receipt
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of treatment for CKD after adjusting for insurance sta-
tus, suggesting an interdependence between these fac-
tors [70]. This same study identified younger age and
residence in a highly populated area as factors that may
increase the relative odds of receiving treatment. Poor
socioeconomic status has been shown to have a strongly
negative effect on survival in African Americans, but not
for whites. The adjusted relative risk of death decreased
for African Americans by 3% per $1000 increase in yearly
income (P < 0.01) [63].
Culture
Culture plays an important role in forming attitudes to
health care, including how illness is perceived, and what
form treatment should take [71]. For instance, cultural dif-
ferences mean that Japanese, Filipino, and Native Hawai-
ian populations are more likely to have attitudes towards
illness and health care that may conflict with those of
Western medicine. These attitudes may rely on spiritual
and religious beliefs rather than a dependence on modern
pharmacology, and hence there may be skepticism to-
wards Western medical practices. Accordingly, patients
from these populations may be less inclined to receive
Western medications and health care [72, 73]. Similar
attitudes exist for Alaskan Natives, Native Americans,
Hispanics, and African Americans [71, 74]. Cultural be-
liefs may also affect lifestyle factors, such as dietary be-
havior, physical activity patterns, and attitude toward
body size and weight, thereby contributing to increased
rates of overweight and obesity common among racial
and ethnic minorities.
Cultural beliefs may also limit the number of minority
kidney donors [75, 76]. For example, the attitudes of Na-
tive Americans are due, at least in part, to spiritual beliefs,
which hold that the body must be whole after death to en-
ter the spirit world. Indeed, a recent study, conducted in
Maryland, showed that African Americans were three
times less likely than their white counterparts to be listed
as donors on their driver’s licenses [77]. Evidence suggests
that there is greater willingness among Native Americans
to be a living rather than a cadaveric donor (81% versus
54%, respectively) [75]. There is greater willingness to do-
nate when the potential donor is approached by a health
care worker from their own culture, has had personal ex-
perience of ESRD, or is educated and understands the
disease. Physicians need to be aware of the cultural barri-
ers that may exist and how they impact on the treatment
of CKD and ESRD.
Pharmacologic intervention
Studies of inhibitors of the renin-angiotensin-
aldosterone system (RAAS) reported before 2001
included too few African American patients to demon-
strate an improvement in CKD or cardiovascular out-
comes for this subgroup [78, 79]. Furthermore, there
was evidence of a reduced hypertensive response among
African Americans receiving RAAS inhibitor monother-
apy, and a lesser reduction in mortality among African
Americans with left ventricular hypertrophy [80, 81].
Therefore, hypertensive African American patients were
thought to be unlikely to show improved clinical out-
comes with RAAS inhibitors. However, the African
American Study of Kidney Disease and Hypertension
(AASK) showed that RAAS inhibitors can significantly
improve clinical outcomes in African Americans with
hypertensive nephropathy [82]. AASK patients treated
with the angiotensin-converting enzyme (ACE) inhibitor,
ramipril, showed a lower rate of clinical renal events and
death and a lower incidence of new-onset type 2 diabetes
mellitus. The outcome from the AASK is an important
one given the high incidence of hypertensive ESRD in
the African American population, and the fact that data
from previously reported studies had led to low usage
of RAAS inhibitors as primary therapy in this high-risk
subgroup. This low rate of RAAS inhibitor use among
African Americans may contribute to the disproportion-
ate burden of CKD among African Americans compared
with whites.
Unfortunately, the rate of ACE inhibitor–related seri-
ous side effects is greater in racial/ethnic minorities [83].
Thus, inclusion of minorities in studies of angiotensin re-
ceptor blockers (ARBs) is of critical importance. Recent
studies of the ARBs irbesartan [84] and losartan [85] in-
volved higher numbers of racial/ethnic minorities: 13%
African Americans and 5% Hispanics in the former and
15% African Americans and 18% Hispanics in the latter.
Although the numbers were insufficient to perform sepa-
rate subanalyses, the results of these studies with modest
minority enrollment demonstrating enhanced outcomes
in participants receiving ARBs suggest that they are safe
and effective for minority subgroups.
Dialysis
Late referral to a nephrologist, which is common
among minority groups, is associated with the use of syn-
thetic grafts rather than autologous arteriovenous fistulas
as the choice of vascular access [86]. This may be one rea-
son why African Americans are more likely than white
Americans to have synthetic grafts for vascular access
prior to hemodialysis, despite the higher rates of throm-
bosis and infection associated with such devices [86].
A lower than required dose of hemodialysis (with re-
spect to dialyzer clearance per unit of time) is associated
with increased mortality when all demographic groups
are evaluated together. African American patients are
more likely than white patients to receive a lower than
required dose of hemodialysis (a mean Kt/V of 1.36 ver-
sus 1.40, respectively) and the reasons for this are not
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can Medical Association (JAMA 280:1764–1768, 1998). Copyright ( c©)
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known [87, 88]. However, survival outcomes for African
Americans appear to be less sensitive to lower doses of
hemodialysis compared with white patients who have a
lesser tolerance to lower urea reduction ratios (URR)
(Fig. 4) [87, 88]. In at least one study it was proposed
that the lower URR in African Americans may be a con-
sequence of a larger urea distribution volume as these
patients had, on average, greater body weights, total
body volume, body surface area, serum albumin levels,
and serum creatinine levels than white Americans [87].
Other factors may include selective survival, increased
access to medical care, and increased physician/health
care provider interaction following the initiation of re-
nal replacement therapy associated with the provision of
insurance through Medicare.
Surprisingly, racial/ethnic minorities with ESRD on
dialysis live longer than their white counterparts [4].
Several possible reasons for this have been proposed,
including survival bias, lower rates of renal replacement
therapy for minorities with more severe versus less severe
comorbidity, and selection of healthier white patients for
transplant compared with minorities [89]. Nevertheless,
the precise reason for this finding remains undetermined
[16]. Understanding the reasons underlying these differ-
ences could have an important impact on strategies to
improve survival outcomes for all dialysis patients.
Transplantation
Given the predominantly white donor population in
the United States, ethnic minority ESRD patients are at
an obvious disadvantage in their chances of receiving a
suitable kidney. This situation is compounded by lower
levels of organ donation among minority groups due, at
least in part, to many of the cultural factors discussed ear-
lier [75, 90, 91]. African Americans are much less likely
than whites to have been referred for evaluation at a
transplant center, placed on a waiting list, or have re-
ceived a transplant [92]. These racial/ethnic differences in
access to transplantation remained significant even after
adjustment for patient preference, health status, sociode-
mographic factors, perceptions of care, and comorbidities
[92]. A survey of nearly 300 nephrologists in four regions
of the United States showed that physicians believed that
this reduced referral rate was due to patient preference,
availability of living donors, failure to complete evalua-
tions, and comorbid conditions [93]. Approximately 50%
of the nephrologists surveyed reported that comorbidities
and inability to complete pretransplant evaluations were
the major reasons accounting for differences in referral
rates [93]. This is supported by previous research, which
showed that African American patients were less likely
than white patients to be considered appropriate candi-
dates for transplantation (9% versus 21%, respectively)
and were more likely to have had an incomplete workup
(47% versus 39%) [90]. The most common reasons why
patients were considered inappropriate for transplanta-
tion were a body mass index over 35, presence of an
active infection and presence of extrarenal, noncardiac
comorbidities. Among patients considered suitable for a
transplant, African Americans are less likely than white
patients to actually receive a transplant (17% versus 52%,
respectively) [90]. It has been suggested that these differ-
ences may be the result of institutional racism. Indeed
the Institute of Medicine concluded in their recent re-
port on the racial and ethnic disparities in health care
that “although myriad sources contribute to these dis-
parities, some evidence suggests that bias, prejudice, and
stereotyping on the part of health care providers may con-
tribute to differences in care” [94]. A study by Alexander
and Sehgal [61] showed that cadaveric transplant rates be-
tween African Americans and whites vary considerably
(rate per 100 patient-years 5.1 versus 11.6, respectively)
(Fig. 5). African Americans were much less likely than
whites to complete the final three steps of the trans-
plant process, being definitely interested in transplan-
tation (odds ratio 0.68), completing the pretransplant
workup (odds ratio 0.56), and moving up the waiting list
and receiving a transplant (odds ratio 0.50) [61]. A re-
cent study, which examined the effect of human leuko-
cyte antigen (HLA) typing on the allocation of cadav-
eric kidney transplants in white and nonwhite patients,
found that the current policy regarding HLA matching is
another factor that contributes to the reduced transplan-
tation rate among nonwhites [95]. Current policy gives
priority to candidates with no HLA A, B, or DR mis-
matches, followed by candidates with the fewest mis-
matches at the HLA B and DR loci. This policy is
based on the graft survival rate of first cadaver kidney
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transplants with a complete mismatch (six HLA A + B +
DR mismatches) being 17% lower than that of grafts with
no mismatch [96], and the racial distribution of these loci
happens to result in whites receiving transplants more
frequently. A recent modeling of the risk of graft fail-
ure by race and HLA DR and HLA B suggested that
maintaining HLA DR matching and eliminating HLA B
matching as a priority would improve the racial equality
in transplant allocation while having little effect on graft
loss.
Another factor contributing to the racial differences
in transplantation access rates is the belief of physicians
that transplantation prolongs survival less compared with
dialysis for African Americans than whites [93]. Although
a greater survival benefit from renal transplantation has
been observed in whites compared with African Ameri-
cans, the average survival benefit of transplantation rela-
tive to dialysis is significant for both patient groups [97].
If physicians perceive the survival benefit to be less in
African Americans they may be less likely to advocate
this treatment option. Physician bias may also result in
ineffective communication with patients and a lack of
information exchange between physician and patient re-
garding treatment choices [93].
It has been reported previously that African
Americans who receive a renal transplant are 1.8 times
more likely to suffer long-term graft failure than whites
or other ethnic groups, such as Hispanics and Native
Americans [90, 97–99]. This rate of graft failure was
not due to differences in haplotype matching or socioe-
conomic factors, such as disparities in insurance status.
The introduction of newer, more effective immunosup-
pressive therapies represents an important advance in
achieving improved patient outcomes and reducing the
existing disparities. In a study of 120 African Ameri-
cans and 65 whites who received renal transplants with
tacrolimus-based immunosuppression and were followed
for 34 months, Hardinger et al [100] reported no differ-
ence in 5-year actuarial patient and graft survival rates.
However, the mean time to chronic allograft nephropa-
thy was shorter in African American recipients (18 versus
37 months, respectively) (P = 0.03). In another study of
57,926 patients who had received a renal transplant and
the immunosuppressive mycophenolate mofetil, 3-year
patient survival and death-censored graft survival rates
were similar for African American and white renal trans-
plant recipients [101].
Racial differences in transplantation rates are also seen
in the predominantly ethnic population of Hawaii, whose
inhabitants have a greatly reduced likelihood of receiv-
ing kidney transplants compared with patients living in
the continental United States [4]. Similarly, indigenous
peoples in Australia and New Zealand are less likely to
undergo renal transplantation and have higher posttrans-
plant mortality rates compared with nonindigenous pop-
ulations [11, 12].
ADDRESSING THE RACIAL DISPARITIES
IN CKD
Innovative initiatives are required that will target in-
dividuals at greatest risk of CKD to ensure they receive
appropriate and timely intervention to slow or eliminate
progression to ESRD. These initiatives may help reduce
the dramatic racial disparities in ESRD. A recent anal-
ysis by Rodriguez and colleagues noted significant dif-
ferences in serum creatinine values across three Latino
subgroups, Mexican Americans, mainland Puerto Ricans,
and Cuban Americans. Indeed, Puerto Ricans (odds ratio
1.74) and Cuban Americans (odds ratio 4.59) were signifi-
cantly more likely than Mexican Americans to have an es-
timated GFR <60 mL/min/1.73 m2, highlighting the need
for additional studies to assess renal function and CKD
among Latino subgroups to better understand which pop-
ulations are truly at increased risk [102].
Screening programs to identify individuals at risk of
CKD and provide early treatment and advice would likely
help reduce the number of ESRD cases. Such an ap-
proach is particularly pertinent where diet, nonadherence
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to pharmacologic treatment, and other modifiable factors
play a role. Access to healthcare and timely referral to
a nephrologist for those with a low socioeconomic sta-
tus would be improved by increased funding for publicly
available health care for CKD. Unfortunately, the short-
age in the nephrology workforce and the growing ESRD
population, which will be sustained by the aging United
States population, contribute to the limitations in provid-
ing optimal early CKD care [103]. This situation needs
to be addressed through enhanced CKD education for
primary care providers with the strategic integration of
consultative services and a collaborative patient centered
approach.
Education directed toward patients and physicians is
important for overcoming the many cultural differences
in health beliefs and behaviors that contribute to both the
risk and progression of CKD. Adherence to referral and
treatment for CKD may be improved when patients feel
they receive health recommendations in a respectful and
culturally considerate manner. Increasing the number of
minority physicians practicing within their own commu-
nities may further help reduce some of these cultural
barriers.
Physician education is also required to improve patient
access to transplantation. The critical reexamination and
updating of transplant allocation policies may reduce the
racial imbalance currently seen in transplant allocation.
In addition, the administration of newer, more power-
ful immunosuppressive agents reduces the concerns of
suboptimal graft survival among minorities. Identifying
and understanding the psychosocial barriers to the ac-
cess of renal transplantation and how they affect specific
steps within the transplant process should help to improve
transplantation rates for minorities. It is also especially
important to increase patient education regarding trans-
plantation and reinforce the need for increased kidney
donation from cadaveric and living donors within minor-
ity communities.
To address the educational deficit that exists with re-
gard to kidney diseases, the National Institute of Diabetes
Digestive and Kidney Diseases has recently launched
the National Kidney Disease Education Program [104].
The first priority for outreach efforts is among African
American communities. Pilot studies involving African
American adults and primary care providers were
conducted in four communities in the United States
(Atlanta, Baltimore, Cleveland, and Jackson). This ed-
ucation program aims to raise awareness of the risk fac-
tors and seriousness of CKD, the importance of testing
those at high risk, and the availability of treatment to pre-
vent or slow kidney failure. It also aims to increase access
to kidney disease information and educational materials.
In conjunction with the pilot program, a random phone
survey was carried out in 2017 African Americans aged
30 years and older in seven urban areas to assess their
awareness of CKD. Although 90% of the respondents
had heard of CKD and 67% knew someone with ESRD,
only 8% identified CKD as a negative health outcome
of unchecked hypertension, and only 17% identified it as
a negative health outcome of unchecked diabetes. This
survey showed that in the African American community
awareness of CKD is high but knowledge of the magni-
tude of the illness, its lack of symptoms, its predisposing
risk factors, and strategies for prevention and treatment
are very low [abstract F-PO1031; Hostetter T, et al, J Am
Soc Nephrol 14:289A, 2003]. The findings of this study
are being used to develop and implement the national
“You Have the Power to Prevent Kidney Disease” cam-
paign. These and similar educational efforts also support
the development and validation of emerging CKD thera-
pies by improving the likelihood of minority recruitment
into clinical trials.
CONCLUSION
The racial/ethnic disparities in the incidence, preva-
lence, and treatment of ESRD are well documented
and vary between different minority groups. Despite the
progress made, the causes of CKD and the racial/ethnic
disparities therein, are not fully understood. Although
modifiable risk factors, such as diet, access to medical care
and socioeconomic status contribute to a large propor-
tion of ESRD cases, many risk factors, including emerg-
ing biomarkers, remain to be discovered. Additional
factors, such as suboptimal diabetes management, inad-
equate blood pressure control, and underutilization of
RAAS inhibitors among minorities, may also contribute
to increased rates of CKD progression to ESRD. Further
medical research to better understand the multiple fac-
tors contributing to CKD disparities, such as barriers to
transplantation and mechanisms of increased hemodial-
ysis survival among minorities, will benefit clinical out-
comes not only for minority patients, but for all patients
with kidney disease. However, to improve the care of
disenfranchised communities globally, simultaneous ef-
forts to address lingering social injustices and institutional
forms of racism that perpetuate limited educational op-
portunities, socioeconomic imbalances, and limited ac-
cess to healthcare are needed to ensure the contributions
of advancing medical care will have a clinically relevant
impact on improving patient outcomes.
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